EEI-BIOTECHFINANCES Eléments Essentiels d'Information / Essential Elements of Information
Tuesday, October 22nd 2019 at 1:00pm UTC SCOTTSDALE, Ariz.–(BUSINESS WIRE)– Systems Oncology, LLC (“SO”) and The Pritzker Organization, LLC (“TPO”) announced today that Pritzker Family Business Interests advised by TPO have invested in the first closing of SO’s Series B round. The funding will be used to invest in both …
Plus »3M Supports Nobel Prize Dialogue Event Focused on Health in Berlin
Tuesday, October 22nd 2019 at 8:00pm UTC Nobel laureates and world-leading thinkers to discuss health and wellbeing at free-of-charge event titled ‘Towards Health’ on Nov. 8 BERLIN–(BUSINESS WIRE)– On November 8, the acclaimed Nobel Prize Dialogue event will be making its first visit to Berlin to explore scientific and societal …
Plus »RAPT Therapeutics Strengthens Board with Addition of Veteran Biotechnology Executive Wendye Robbins, M.D.
Tuesday, October 22nd 2019 at 12:00pm UTC SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)– RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company developing oral small molecules for oncology and inflammatory diseases, today announced the addition of Wendye Robbins, M.D., president and CEO of Blade Therapeutics, Inc., to the company’s board of directors. …
Plus »VBI Vaccines Announces Late-Breaker Poster Presentation at The Liver Meeting® 2019
Tuesday, October 22nd 2019 at 12:00pm UTC CAMBRIDGE, Mass.–(BUSINESS WIRE)– VBI Vaccines Inc. (Nasdaq: VBIV) (« VBI »), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that the company’s abstract titled, “Rapid Increase in Anti-HBsAg Titers and Higher Seroprotection Rates in Adults Immunized with Sci-B-Vac Compared to …
Plus »Veracyte Announces New Data Demonstrating That Envisia Genomic Classifier Improves IPF Diagnosis
Monday, October 21st 2019 at 1:57pm UTC Results From Three Studies Presented at CHEST 2019 Suggest Test Increases Physicians’ Confidence in Diagnosis and Can Reduce the Need for Invasive, Risky Procedures SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)– Veracyte, Inc. (Nasdaq: VCYT) announced that data from three studies presented at the annual …
Plus »Exicure to Present at 2019 BIO Investor Forum
Monday, October 21st 2019 at 8:32pm UTC CHICAGO & CAMBRIDGE, Mass.–(BUSINESS WIRE)– Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced today that its chief financial officer, David Snyder, will give a company update on Tuesday, October 22, 2019 at …
Plus »Bicycle Therapeutics Expands Neuroscience Collaborations to Include Oxford University’s Oxford Drug Discovery Institute
Tuesday, October 22nd 2019 at 7:00am UTC Bicycle to collaborate with ODDI, an organization with deep expertise in the molecular pathology of Alzheimer’s disease and CNS drug development CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)– Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based …
Plus »Intensity Therapeutics’ Intratumoral INT230-6 Tumor Regression and Immune Response Activity Data Selected for Oral Presentation at SITC 2019 Conference
Tuesday, October 22nd 2019 at 11:35am UTC WESTPORT, Conn.–(BUSINESS WIRE)– Intensity Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary intratumoral immunotherapy products to kill tumors and increase immune system recognition of solid cancers, today announced that data from the ongoing clinical trial of its lead product candidate INT230-6 was selected …
Plus »Odonate Therapeutics Announces Completion of Enrollment in CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Metastatic Breast Cancer
Monday, October 21st 2019 at 12:30pm UTC SAN DIEGO–(BUSINESS WIRE)– Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced the completion of enrollment in CONTESSA, a multinational, multicenter, randomized, Phase 3 study …
Plus »CheckMate -9LA, a Phase 3 Trial Evaluating Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) Combined with Chemotherapy, Meets Primary Endpoint Demonstrating Superior Overall Survival Compared to Chemotherapy Alone in First-Line Lung Cancer
Tuesday, October 22nd 2019 at 10:59am UTC Study evaluated Opdivo plus low-dose Yervoy given concomitantly with two cycles of chemotherapy vs. chemotherapy alone for the first-line treatment of advanced non-small cell lung cancer PRINCETON, N.J.–(BUSINESS WIRE)– Bristol-Myers Squibb Company (NYSE: BMY) today announced that CheckMate -9LA, a pivotal Phase 3 …
Plus »
